An Open-Label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Fruguintinib in Combination with Tislelizumab in Patients with Advanced Triple Negative Breast Cancer

Debu Tripathy ¹, Stacey M. Ukrainskyj ², Zhao Yang³, Marek Kania², William R. Schelman², Erika Hamilton ⁴ ¹The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, US; ²HUTCHMED International, Florham Park, NJ, US; ³Hutchison MediPharma, No. 4, 720 Cailun Road, Zhangjiang, Shanghai, China 20120; ⁴Sarah Cannon Research Institute/Tennessee Oncology, 250 25th Ave N, Nashville, TN 37203, US

INTRODUCTION

Immune checkpoint inhibitors (ICIs) have improved clinical outcomes in triple negative breast cancer (TNBC) and in endometrial cancer (EC), but many patients (pts) do not respond

to ICIs or will develop resistance.1

- Combining VEGFR inhibitors with ICIs (with demonstrated) clinical efficacy in TNBC and EC) may potentiate efficacy and suppress tumor growth and reduce metastasis² by:
- Normalizing vascular immune crosstalk
 - Improving immune effector cell infiltration
- Fruquintinib: a novel, highly selective, oral, tyrosine kinase inhibitor of VEGF-1, 2, 3 administered orally 5 mg/daily on a 3week on, 1-week off schedule.
- Tislelizumab: a humanized, IgG4-variant monoclonal antibody against PD-1, administered intravenously, 300 mg, on Day 1 of each 4-week cycle.
- Safety and preliminary efficacy of fruguintinib have been demonstrated in metastatic breast cancer, including TNBC.
 - Phase 1 study in China (2009-013-00CH1)
 - Ongoing phase 1/1b study in the US (2015-013-00US1)
- This open-label, phase 1b/2 study (NCT04579757) will assess safety, PK, and efficacy of fruguintinib in combination with tislelizumab in pts with:
 - Locally advanced or metastatic TNBC, independent of PD-L1 status, (immunotherapy (IO) pre-treated and naïve)
 - EC (IO-naïve) in the second line setting
- Hypothesis: Addition of fruguintinib can enhance the clinical activity of or potentially overcome resistance to ICI and improve clinical activity in TNBC and EC.

METHODS


- The study consists of a safety lead-in phase (Part 1) and dose expansion phase (Part 2).
- Part 1: Assess safety and tolerability of fruguintinib and tisleizumab and confirm RP2D of the combination.
- Part 2: Determine the clinical activyDetermine clinical activity and safety of the combination at the RP2Din pts with TNBCand EC.
- Patients will be treated until radiologically determined progressive disease per RECISTv1.1, unacceptable toxicity, death, or withdrawal from study.

- Hist ologically or TNBC or EC
- ION



- metastatic setting.

STUDY DESIGN



2L=second line; ECOG=Eastern Cooperative Oncology Group; EC=endometrial cancer; IO=immuno-oncology; n=total number of subjects; PS=performance status; QD=once daily; PO=orally; IV=intravenous; Q4W=once every 4 weeks; TNBC=triple negative breast cancer; *defined by IO agents given in the metastatic setting

KEY INCLUSION CRITERIA

Cohorts Aand B: Histologically or cytologically confirmed, locally advanced or metastatic TNBC (per American Society for Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines).

• TNBC progressed on at least 1, but not >3, prior lines of cytotoxic therapy in the metastatic setting.

• For pts who recur within 12 months of adjuvant therapy, adjuvant therapy will count as 1st line chemotherapy in the metastatic or recurrent setting.

Cohort C: Histologically or cytologically confirmed, locally advanced, metastatic or recurrent EC.

• EC must have progressed on 1 prior platinum-based chemotherapy. • Pts may have received up to 1 additional line of platinum-based chemotherapy if given in the neoadjuvant or adjuvant setting. • Pts must not have received an ICI or other immunotherapy.

■ IO-treated and IO-naïve pts are defined by prior IO agents in the

Tumor tissue collected for:

• Retrospective analysis of PD-L1 expression.

• Exploratory biomarkers related to response and resistance.

Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

Measurable disease according to RECIST version 1.1.

Expected survival ≥ 12 weeks.

KEY EXCLUSION CRITERIA

- Adverse events (AEs) due to previous anti-tumor therapy that have not recovered to \leq CTCAE Grade 1,
 - Except alopecia and peripheral neurotoxicity (≤CTCAE Grade 2).
- Other malignancies that have been adequately treated during the 5 years prior to screening.
- Except non-melanoma skin cancer, *in situ*cervical cancer, or bladder cancer (Tis and T1).
- Brain metastases and/or spinal cord compression untreated with surgery and/or radiotherapy.
 - Excluding pts requiring steroids within 4 weeks prior to start of study drug.
- Systemic anti-neoplastic therapies or any investigational therapy within 4 weeks prior to the first dose of study drug.
- drug

Systemic small molecule-targeted therapies (e.g., tyrosine kinase inhibitors) within 5 half lives or 4 weeks (whichever is shorter) prior to the first dose of study

Palliative radiotherapy for bone metastasis/lesion within 2 weeks prior to the initiation of study drug.

OBJECTIVES: Part 1

Primary Objectives		Primary E
Confirm recommended phase 2 dose (RP2D) of fruquintinib in combination with tislelizumab	•	RP2D
Assess the safety and tolerability of fruquintinib in combination with tislelizumab	•	Occurrence and adverse events Relative dose in modification Electrocardiogn clinical laborate
Secondary Objectives		Secondary
Evaluate the anti-tumor activity of fruquintinib in combination with tislelizumab		Objective response Disease control Duration of response Progression-fre Overall survival
activity of fruquintinib in	•	Disease control Duration of resp Progression-fre

STATISTICAL ANALYSIS

- The primary efficacy and safety population will include pts who received at least 1 dose of fruquintinib or tislelizumab.
- Data will be summarized using descriptive statistics.
- No formal hypothesis testing is planned.
- Kaplan-Meier method will be used to summarize the time to event endpoints (DoR, PFS, OS).
- The point estimate and its associated 95% Clopper-Pearson confidence interval (CI) will be provided for binary endpoints (ORR, DCR).
- Analyses will be conducted using SAS® (version 9.1 or higher).

#3495

OBJECTIVES: Part 2

Indpoints

nd severity of (AE) intensity and dose

gram (ECG) and tory abnormalities

Endpoints

onse rate (ORR) ol rate (DCR) sponse (DoR) ee survival (PFS) al (OS)

ntrations of nd Ml1 metabolite

ntrations of nd anti-drug A) response to

Primary Objective	Primary Endpoint
Evaluate the ORR of fruquintinib in combination with tislelizumab	• ORR
Secondary Objectives	Secondary Endpoints
Further evaluate the anti-tumor activity of fruquintinib in combination with tislelizumab	 DCR DoR PFS OS
Assess the safety and tolerability of fruquintinib in combination with tislelizumab	 Occurrence and severity of adverse events (AE) Relative dose intensity and dose modification ECG and clinical laboratory abnormalities
Characterize the PKprofile of fruquintinib in combination with tislelizumab	• Plasma concentrations of fruquintinib and Ml 1 metabolite
Evaluate the immunogenicity of fruquintinib in combination with tislelizumab	• Serum concentrations of tislelizumab and ADA response to tislelizumab
Detect the expression of PD-L1 and other biomarkers in tumor tissues and evaluate their association with study drug, anti- tumor activity, and safety	 Changes from baseline in tumor markers Associations between tumor biomarkers and drug exposure, efficacy and safety parameters
DISCLOSURES D Tripathy discloses research funding paid directly to the institution from Novartis and Polyphor and receipt of fees for consulting, educational lectures, and participation in steering committees and advisory boards from Pfizer, Exact Sciences, GlaxoSmithKiline, OncoPep and Immunomedics. WR Schelman, SMUkrainskyj, Z Yang, and MKania ar employed by HUTCHMED.	their families who participated in this trial.We would like to thank all investigators, study coordinators and the entire project team.
References	O Copies of this poster

- . Hossain et al. *Cancers*2021 13:373
- 2. Li et al. *Clin Cancer Res*20 Apr 1;26(7):1712-1724



obtained through Quick Response (QR) Code are for • The sponse (QR) code are for personal use only and may not be reproduced without permission from the author of this poster.